Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long‐Acting Intramuscular Injections

Documenti analoghi

• A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV
  di: Kelong Han, et al.
  Pubblicazione: (2025)
• LP‐001, a Novel Long‐Acting EPO‐Fc Fusion Protein: A Phase I Dose‐Escalation Study of Pharmacokinetics, Safety, and Tolerability in Healthy Chinese Subjects
  di: Jie Yang, et al.
  Pubblicazione: (2026)
• Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study
  di: Aravind Mittur, et al.
  Pubblicazione: (2026)
• Lack of Concentration‐QTc Relationship and Cardiac Risk With Vatiquinone Therapeutic and Supratherapeutic Doses
  di: Lucy Lee, et al.
  Pubblicazione: (2024)
• Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect
  di: Jing Zhang, et al.
  Pubblicazione: (2025)